Medizinische Onkologie

Uzm. Dr. Barış Gezici

Arzt und Forscher İzmir Şehir Hastanesi İzmir
Seite der Einrichtung öffnen
Korrektur vorschlagen

Ist das Ihr Profil? Beanspruchen Sie es und bestätigen Sie Ihre Angaben.

Profil beanspruchen

Vertrauen

Woher stammen diese Angaben?

Neben jeder Angabe steht ihre Quelle. Wenn Sie einen Fehler entdecken, können Sie eine Korrektur vorschlagen.

  • FachgebietMedizinische Onkologiesaglik.gov.trAus der Quelle
  • Einrichtungİzmir Şehir Hastanesisaglik.gov.trAus der Quelle
  • Publikationen10 PublikationenOpenAlex, Europe PMCAus der Quelle
  • ORCID0000-0003-1151-6523ORCIDAus der Quelle
  • Letzte Synchronisierung5. November 2026 09:07https://izmirsehir.saglik.gov.tr/TR-1046789/doktorlarimiz.html#baris-gezicisaglik.gov.tr

Wissenschaftliche Arbeiten

Publikationen

10 Publikationen

  1. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  2. Successful rapid desensitization with 5-fluorouracil in a patient with metastatic sigmoid colon cancer: A case report

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261478571 PMID 42585552 Quelle: OpenAlex

  3. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 Zitationen (Europe PMC) Quelle: OpenAlex

  4. Prevalence of Insomnia and Associated Factors in Female Patients Undergoing Chemotherapy

    Nature and science of sleep, 2025

    DOI 10.2147/nss.s554960 PMID 41084526 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  5. CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01500-8 Quelle: OpenAlex

  6. POSTER: CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00889-3 Quelle: OpenAlex

  7. CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01501-x Quelle: OpenAlex

  8. POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00914-x Quelle: OpenAlex

  9. CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01488-x Frei zugänglicher VolltextQuelle: OpenAlex

  10. POSTER: CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00888-1 Quelle: OpenAlex